Biotechnology developer Molecular Targeting Technologies has received investigational new drug approval from U.S. Food and Drug Administration (FDA) to study EBTATE use in patients with neuroendocrine tumors.
EBTATE is used for targeted radionuclide therapy and is used to append Evans blue (EB) to a targeting radiopharmaceutical. EB binds reversibly to serum albumin, enhancing radiotherapeutic time window with longer circulation half-life and increasing tumor uptake to improve outcomes.
